Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SITFC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN115429893A ADC15
|
|||||
| Synonyms |
CN115429893A ADC15
Click to Show/Hide
|
|||||
| Organization |
Bio Thera Solutions Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.7
|
|||||
| Antibody Name |
B7H3 antibody
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
62.02
|
%
|
Undisclosed | Undisclosed |
| Tumor Growth lnhibition value (TGl) |
62.02
|
%
|
Undisclosed | Undisclosed |
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 62.02% | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | 62.02% | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
|
||||
| In Vivo Model | Hep-3 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | . nM | Negative B7H3 expression (B7H3-) | ||
| Method Description |
5000 CHO-K1 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1 cells | CVCL_0214 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.77 nM | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1-B7-H3 cells | CVCL_0214 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.77 nM | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Normal | CHO-K1-B7-H3 cells | CVCL_0214 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 68.75 nM | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 68.75 nM | Positive B7H3 expression (B7H3+++/++) | ||
| Method Description |
5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | Calu-6 cells | CVCL_0236 | ||